CSPHF - Week In Review: Broncus Stages $200 Million Hong Kong IPO For Pulmonary Devices

• Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion.
• Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survival from 5.8 months to 9.0 months in Stage III NSCLC patients.
• IMPACT Therapeutics of Nanjing will collaborate with Toronto's Cyclica using Cyclica's Ligand Express data-based platform to assess the "targetivity" of their novel oncology candidates.

For further details see: